KR20240099410A - 신규한 폴리펩티드 - Google Patents
신규한 폴리펩티드 Download PDFInfo
- Publication number
- KR20240099410A KR20240099410A KR1020247018489A KR20247018489A KR20240099410A KR 20240099410 A KR20240099410 A KR 20240099410A KR 1020247018489 A KR1020247018489 A KR 1020247018489A KR 20247018489 A KR20247018489 A KR 20247018489A KR 20240099410 A KR20240099410 A KR 20240099410A
- Authority
- KR
- South Korea
- Prior art keywords
- polypeptide
- domain
- mutation
- mutations
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2115925.6 | 2021-11-05 | ||
| GB202115925 | 2021-11-05 | ||
| GB2204539.7 | 2022-03-30 | ||
| GBGB2204539.7A GB202204539D0 (en) | 2022-03-30 | 2022-03-30 | Novel peptides |
| GBGB2212801.1A GB202212801D0 (en) | 2022-09-02 | 2022-09-02 | Novel peptides |
| GB2212801.1 | 2022-09-02 | ||
| PCT/EP2022/080860 WO2023079101A2 (en) | 2021-11-05 | 2022-11-04 | Novel polypeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240099410A true KR20240099410A (ko) | 2024-06-28 |
Family
ID=84329469
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247018489A Pending KR20240099410A (ko) | 2021-11-05 | 2022-11-04 | 신규한 폴리펩티드 |
| KR1020247018934A Pending KR20240114794A (ko) | 2021-11-05 | 2022-11-04 | 신규 펩티드 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247018934A Pending KR20240114794A (ko) | 2021-11-05 | 2022-11-04 | 신규 펩티드 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US20260001961A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4426733A2 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2024542142A (cg-RX-API-DMAC7.html) |
| KR (2) | KR20240099410A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022381977A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3237463A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL312556A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024005508A (cg-RX-API-DMAC7.html) |
| WO (2) | WO2023079102A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20260001961A1 (en) * | 2021-11-05 | 2026-01-01 | Alligator Bioscience Ab | Novel polypeptides |
| JP2026515781A (ja) * | 2023-04-13 | 2026-05-19 | アリゲーター・バイオサイエンス・アーベー | 併用療法 |
| CN117924468B (zh) * | 2023-12-08 | 2024-09-20 | 南京大学 | 一种靶向登革热病毒ns1蛋白纳米抗体的制备方法和应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| SE459005B (sv) | 1985-07-12 | 1989-05-29 | Aake Rikard Lindahl | Saett att framstaella sfaeriska polymerpartiklar |
| CA2192782C (en) | 1995-12-15 | 2008-10-14 | Nobuyuki Takechi | Production of microspheres |
| LT2691417T (lt) | 2011-03-29 | 2018-10-25 | Roche Glycart Ag | Antikūno fc variantai |
| GB201115280D0 (en) * | 2011-09-05 | 2011-10-19 | Alligator Bioscience Ab | Antibodies, uses and methods |
| CA2980189A1 (en) * | 2015-04-24 | 2016-10-27 | Genentech, Inc. | Multispecific antigen-binding proteins |
| CA3049791A1 (en) * | 2017-01-27 | 2018-08-02 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| EP3898681A2 (en) * | 2018-12-17 | 2021-10-27 | Alligator Bioscience AB | Polypeptides |
| GB201820556D0 (en) | 2018-12-17 | 2019-01-30 | Alligator Bioscience Ab | Novel polypeptides |
| AU2020357944A1 (en) * | 2019-09-30 | 2022-03-31 | Adimab, Llc | CH1 domain variants engineered for preferential light chain pairing and multispecific antibodies comprising the same |
| EP4048701A4 (en) | 2019-10-23 | 2024-05-29 | Lyvgen Biopharma Holdings Limited | Anti-cd40 binding molecules and bi-specific antibodies comprising such |
| KR20220147583A (ko) * | 2020-01-09 | 2022-11-03 | 바이오뮤넥스 파마슈티컬스 | Mait 및 종양 세포 둘 모두에 결합하는 다중특이적 항체 |
| US20260001961A1 (en) * | 2021-11-05 | 2026-01-01 | Alligator Bioscience Ab | Novel polypeptides |
-
2022
- 2022-11-04 US US18/703,623 patent/US20260001961A1/en active Pending
- 2022-11-04 IL IL312556A patent/IL312556A/en unknown
- 2022-11-04 WO PCT/EP2022/080861 patent/WO2023079102A2/en not_active Ceased
- 2022-11-04 CA CA3237463A patent/CA3237463A1/en active Pending
- 2022-11-04 MX MX2024005508A patent/MX2024005508A/es unknown
- 2022-11-04 KR KR1020247018489A patent/KR20240099410A/ko active Pending
- 2022-11-04 JP JP2024526902A patent/JP2024542142A/ja active Pending
- 2022-11-04 EP EP22800717.5A patent/EP4426733A2/en active Pending
- 2022-11-04 EP EP22822279.0A patent/EP4426738A2/en active Pending
- 2022-11-04 US US17/980,751 patent/US11873348B2/en active Active
- 2022-11-04 AU AU2022381977A patent/AU2022381977A1/en active Pending
- 2022-11-04 WO PCT/EP2022/080860 patent/WO2023079101A2/en not_active Ceased
- 2022-11-04 JP JP2024526901A patent/JP2024543043A/ja active Pending
- 2022-11-04 KR KR1020247018934A patent/KR20240114794A/ko active Pending
-
2023
- 2023-11-13 US US18/507,736 patent/US12448465B2/en active Active
-
2025
- 2025-09-15 US US19/329,496 patent/US20260146107A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024542142A (ja) | 2024-11-13 |
| WO2023079101A3 (en) | 2023-06-15 |
| JP2024543043A (ja) | 2024-11-19 |
| IL312556A (en) | 2024-07-01 |
| US20260001961A1 (en) | 2026-01-01 |
| AU2022381977A1 (en) | 2024-05-23 |
| KR20240114794A (ko) | 2024-07-24 |
| US11873348B2 (en) | 2024-01-16 |
| EP4426738A2 (en) | 2024-09-11 |
| US20260146107A1 (en) | 2026-05-28 |
| WO2023079101A2 (en) | 2023-05-11 |
| EP4426733A2 (en) | 2024-09-11 |
| US20240117074A1 (en) | 2024-04-11 |
| US12448465B2 (en) | 2025-10-21 |
| US20230312754A1 (en) | 2023-10-05 |
| MX2024005508A (es) | 2024-09-18 |
| CA3237463A1 (en) | 2023-05-11 |
| WO2023079102A2 (en) | 2023-05-11 |
| WO2023079102A3 (en) | 2023-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11629189B2 (en) | Bispecific antibody for ICOS and PD-L1 | |
| TWI810541B (zh) | 靶向ox40及fap之雙特異性抗原結合分子 | |
| JP7425604B2 (ja) | 抗ctla4-抗pd-1二機能性抗体、その医薬組成物および使用 | |
| KR102427192B1 (ko) | 항-인간 4-1bb 항체 및 그의 용도 | |
| CN110066338B (zh) | 作为T细胞衔接器的双特异性IgG抗体 | |
| WO2020098734A1 (zh) | 抗tigit抗体及其用途 | |
| CN111542546B (zh) | 抗lag-3抗体及其用途 | |
| US20170304437A1 (en) | Bispecific molecules capable of specifically binding to both ctla-4 and cd40 | |
| TW201930353A (zh) | 使用經靶向之ox40促效劑的組合療法 | |
| US12570759B2 (en) | Polypeptides | |
| CN114763385B (zh) | 靶向ror1的抗体及其用途 | |
| WO2018036472A1 (zh) | 一种抗pd1单克隆抗体、其药物组合物及其用途 | |
| US20260001961A1 (en) | Novel polypeptides | |
| JP2025128164A (ja) | 抗trem2抗体の使用方法 | |
| US20250122296A1 (en) | Bispecific antibody and use thereof | |
| KR20200041835A (ko) | 재조합 이중특이적 항체 | |
| CN113677703A (zh) | 多肽 | |
| EP4594345A1 (en) | Protease-activated polypeptides | |
| US20240239912A1 (en) | Targeted reduction of activated immune cells | |
| IL301513A (en) | Antibodies capable of binding to ror2 and bispecific antibodies binding to ror2 and cd3 | |
| CN114616247B (zh) | Ox40/pd-l1双特异性抗体 | |
| CN118434767A (zh) | 新型多肽 | |
| HK40066344B (en) | Ox40/pd-l1 bispecific antibody | |
| HK40066344A (en) | Ox40/pd-l1 bispecific antibody | |
| KR20260023010A (ko) | 인간 ccr8에 결합하는 항체 및 이의 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |